Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurokinin A. A pharmacological study.

D Regoli1, N E Rhaleb, S Dion

  • 1Department of Pharmacology, Medical School, University of Sherbrooke, Canada.

Pharmacological Research
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice.

British journal of pharmacology·2008
Same author

Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance.

Neuropeptides·2007
Same author

Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2.

The journal of peptide research : official journal of the American Peptide Society·2005
Same author

Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice.

Naunyn-Schmiedeberg's archives of pharmacology·2004
Same author

Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.

The journal of peptide research : official journal of the American Peptide Society·2004
Same author

Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test.

The European journal of neuroscience·2003

Neurokinin A, a peptide discovered in 1983, is active on NK-2 receptors. Structure-activity studies identified the minimal structure for NK-2 receptor activation and selective agonists.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Biochemistry

Background:

  • Neurokinin A (NKA) is a decapeptide discovered in 1983 with diverse biological effects in peripheral organs.
  • NKA belongs to the tachykinin peptide family, which includes substance P and neurokinin B.

Purpose of the Study:

  • To review sensitive and selective in vivo and in vitro assays for evaluating NKA.
  • To characterize neurokinin receptors, particularly the NK-2 subtype, by comparing NKA with related peptides.
  • To identify the minimal structural requirements for NK-2 receptor activation and discover selective agonists.

Main Methods:

  • Review of in vivo and in vitro bioassays for NKA.
  • Comparative analysis of NKA, substance P, neurokinin B, and other tachykinins.

Related Experiment Videos

  • Structure-activity relationship (SAR) studies using NKA fragments and analogues, including NKA(4-10) and its derivatives.

    • Main Results:

    • NKA exhibits significant activity at the NK-2 receptor subtype.
    • SAR studies elucidated the minimum structural features necessary for NK-2 receptor activation.
    • Selective NK-2 receptor agonists, such as [Nle10]-NKA(4-10) and [beta-Ala8]-NKA(4-10), were identified.

    Conclusions:

    • Neurokinin A is a key ligand for the NK-2 receptor.
    • Understanding the structure-activity relationships of NKA is crucial for developing selective receptor modulators.
    • The identified selective agonists provide valuable tools for further research into NK-2 receptor function.